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ABSTRACT 
 
Creatine transport has been assigned to creatine transporter 1 (CRT1), encoded by mental 
retardation associated SLC6A8. Here we identified a second creatine transporter (CRT2) known 
as monocarboxylate transporter 12 (MCT12), encoded by the cataract and glucosuria associated 
gene SLC16A12. A non-synonymous alteration in MCT12, (p.G407S), found in a patient with age 
related cataract, lead to a significant reduction of creatine transport. Furthermore, Slc16a12 
knockout rats have elevated creatine levels in urine. Transport activity and expression 
characteristics of the two creatine transporters.are distinct. CRT2 (MCT12) mediated uptake of 
creatine was not sensitive to sodium and chloride ions or creatine biosynthesis precursors, 
breakdown product creatinine or creatine phosphate. Increasing pH correlated with increased 
creatine uptake. Michaelis-Menten kinetics yielded a Vmax = 754.2 pmol/h/oocyte and a Km = 
496.9 µM. Relative expression in various human tissues supports the distinct mutation-associated 
phenotypes of the two transporters. SLC6A8 was predominantely found in brain, heart and muscle 
while SLC16A12 was more abundant in kidney and retina. In the lens, the two transcripts were 
found at comparable levels. We discuss the distinct, but possibly synergistic functions of the two 
creatine transporters. Our findings infer potential preventive power of creatine supplementation 
against the most prominent age-related vision impaired condition.  
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INTRODUCTION 
 
Creatine is an essential component of the cellular energy household. It can either be synthesized 
by the body using the amino acids arginine, glycine and methionine or it can be supplied by 
nutrition. Creatine is transported to target cells via the bloodstream (1). After uptake into the 
cells, the phosphorylated form aids in immediate supply of ATP, especially under high demand 
of energy over a short period of time (2, 3). Transport of creatine across the membrane requires 
the creatine transporter1, CRT1, which is encoded by SLC6A8 located on the X chromosome 
(OMIN 300036). CRT1 consists of twelve transmembrane domains (4, 5). Creatine uptake is 
saturable and requires sodium and chloride ions, enabling creatine transport against its 
concentration gradient (5, 6). SLC6A8 is most abundant in tissues with high energy demand 
including skeletal muscle, heart, brain and retina but also in the intestine and kidney epithelial 
cells (7-9). In this context, it is interesting to note that mutations in SLC6A8 primarily lead to 
mental retardation in male patients (OMIM 300352) (10-12) while kidney related clinical features 
or those affecting vision have not been reported.  
The fourteen members of the monocarboxylate transporters (MCT) family, encoded by the 
SLC16 genes contain also 12 transmembrane domains (13). They display distinct expression 
patterns (14, 15) and half of the MCT transporters, including MCT12 encoded by SLC16A12 
(OMIM 611910), are considered orphans (16). Substrates for the other half are diverse molecules 
including monocarboxylates, such as lactate, pyruvate, and butyrate (MCT1,2,3 and 4) (17),  
thyroid hormones (MCT8) (18) or aromatic amino acids (MCT10/TAT1) (19, 20). The 
localization of MCTs to the plasma membrane requires distinct accessory proteins, such as 
gp70/embigin for MCT2 or CD147/basigin for MCT1, 3, 4 and MCT12 (21-24). Based on 
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mutation analysis, the orphan transporter MCT12 is likely to play a role in energy metabolism, 
since a premature termination codon in the gene SLC16A12 causes cataracts of the human lens 
and glucosuria with elevated, non-diabetic glucose levels in urine (OMIM 612018) (25, 26). 
These findings suggest MCT12-mediated reduced reabsorption of glucose in the proximal 
convoluted tubules in kidney. Likewise, disturbed energy homeostasis within the avascular 
crystalline lens may result in opacities that cause cataracts. To be able to test this hypothesis, 
knowledge of the identity of the substrate is essential. To identify the substrate of MCT12, we 
combined the traditional heterologous Xenopus laevis oocyte expression system with a state-of-
the-art metabolomics approach. Two possible candidates were experimentally tested and one of 
them, creatine, could be verified and characterized as substrate for MCT12. This work 
demonstrates the existence of a second creatine transporter with distinct transport characteristics 
and expression patterns.  
 
RESULTS  
Injection of SLC16A12 cRNA leads to localization of MCT12 at the Xenopus laevis oocyte 
membrane 
Xenopus laevis oocytes were chosen as the experimental system to investigate transport activity 
of MCT12. We either injected human reference or human mutant SLC16A12 cRNA. The 
presence or absence of co-injected chaperone CD147 cRNA was also tested because the 
chaperone CD147 was shown to be necessary for proper localization of MCT12 in HEK293 cells. 
Injection of CD147 cRNA alone served as control. For all conditions when the transporter was 
injected, a positive signal in the cell membrane was detected with MCT12-specific antibodies. 
These results were independent from the presence of the chaperone, suggesting that endogenous 
Xenopus CD147 homologue levels seem sufficient for MCT12 trafficking to the membrane. 
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Oocytes injected with only the chaperone CD147 cRNA did not yield a signal. As expected, 
noninjected oocytes also did not show a positive signal (Figure 1). Specificity of the transporter 
signal was demonstrated by the use of the secondary antibody alone (Figure S1A).The membrane 
marker isolectin B4 (IB4) was used to visualize the membranes in oocytes (Figure S1B). Taken 
together, we concluded that the Xenopus laevis oocyte expression system provides the 
experimental requirements necessary to apply a metabolomics in search for the MCT12 substrate. 
 
Metabolomics approach suggested substrate candidates 
A metabolomics approach was designed to narrow down the number of potential substrate 
candidates. Cell extracts obtained from oocytes that were either injected with CD147only 
(control) or coinjected with CD147 and SLC16A12 cRNA were subjected to the analysis of polar 
metabolites with LC-MS, which yielded 14’720 m/z values (ratio of ion mass (m) and its charge 
(z)). To exclude analytical and chemical noise, analysis was focused on m/z values corresponding 
to known biological metabolites by application of a filter with the metabolites listed in the KEGG 
database (Kyoto Encyclopedia, www.genome.jp/kegg/).This resulted in 553 metabolite hits. The 
observed intensity values of these metabolites were subjected to between-group-analysis (BGA), 
contrasting samples of injected oocyte lysates. This resulted in further reduction to 20 metabolites 
(Table 1). To evaluate these candidates, we considered the maximum fold change (Log2 ratio) as 
well as statistical significance (2way ANOVA). The two candidates, creatine (Log2 ratio=-
2.6485 and P=3.11x10-7) and L-glutamine (Log2 ratio=0.9945 and P=0.0002) displayed 
statistically highest significance. Furthermore, these candidates also belonged to the group of 
monocarboxylates and matched the physiological expectations of energy-related metabolites. 
Creatine yielded the most significant difference between oocytes injected with CD147 cRNA 
alone and those coinjected with CD147 and SLC16A12 cRNA. The log2 ratio of -2.6485 
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corresponds to a 6.3fold reduction in creatine levels (P<0.0001, unpaired t-test) (Figure 2A), 
suggesting efflux of creatine.  
 
Efflux and uptake of creatine by MCT12 
To test whether creatine was indeed specifically transported by MCT12, efflux experiments were 
performed, as suggested by the metabolomics study. The time course (0, 15 and 60 minutes) 
showed a significant increase in radioactivity (desintegrations per minute, DPM) (P < 0.0001, 
ANOVA) in the medium when oocytes were coinjected with the chaperone and SLC16A12cRNA 
(32 ± 3 DPM, 1085 ± 262 DPM, 6869 ± 636 DPM for the three time points, n=9), verifying 
creatine efflux. Only minimal changes (ns, ANOVA) in the level of radioactivity were observed 
in noninjected cRNA (17 ±1 DPM, 68 ±34 DPM, 198 ± 100 DPM, n=9) oocytes and those 
injected with the chaperone CD147 cRNA alone (40 ± 17 DPM, 73 ± 21 DPM, 157 ± 57 DPM, 
n=10). At time points 15 and 60, radioactivity in the medium of oocytes injected with the 
transporter were significantly different from the noninjected and chaperone only injected oocytes 
(P < 0.0001, ANOVA) (Figure 2B). Remaining radioactivity in oocytes after the last time point 
was significantly reduced (P < 0.0001) in coinjected (12,165 ± 991 DPM) compared to 
noninjected (34,418 ± 951 DPM) and CD147 only injected oocytes (31,958± 968DPM, nNI=10, 
nCD147=9, nCD147 + hMCT12=8) (Figure S2). These results confirmed the data obtained from the 
metabolomics study and demonstrated that the efflux of creatine depends on MCT12. In an 
uptake experiment we tested whether creatine transport is bidirectional. In oocytes expressing 
MCT12, creatine uptake was 195 ± 12pmol/h/oocyte compared to 1 ± 0pmol/h/oocyte and 1 ± 
0pmol/hour/oocyte in the noninjected and CD147 only injected controls, respectively (n=10 for 
each group) (Figure 2C). Uptake of creatine was statistically significant compared to controls (P 
< 0.0001, ANOVA, followed by Tukey’s test). Therefore, we conclude that MCT12 transports 
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creatine into and out of a cell, probably depending on the creatine concentration gradient. Uptake 
experiments using L-glutamine as substrate candidate did not yield MCT12 specificity (data not 
shown).  
 
Characterization of creatine transport by MCT12 
To investigate whether the uptake was dependent on substrate concentration, different amounts of 
unlabeled creatine, ranging between 1 and 3000 µM, together with a constant concentration of 
14C creatine were used. The uptake profile followed typical Michaelis-Menten kinetics (Figure 
3A) with a Vmax = 838.8pmol/h/oocyte and Km= 567.4µM. This uptake is specific to MCT12 as 
only the presence of MCT12 supported creatine uptake (P≤ 0.0006, for every concentration 
tested, unpaired t-test, n=7-10 per concentration and experimental group) (Figure 3A).Therefore, 
in the subsequent experiments, the values for CD147 only injected oocytes are considered 
background and will be subtracted from those obtained with MCT12. Creatine uptake by MCT12 
was not dependent on Na+ or Cl- ions (ND96: 180 ± 13 pmol/h/oocyte, Na+ free: 169 ± 8 
pmol/h/oocyte and Cl-  free: 174 ± 16 pmol/h/oocyte, (n=19-25 oocytes per group, P = 0.8002, ns, 
ANOVA) (Figure 3B). Considering the pH (pH 7.4: 197 ± 13 pmol/h/oocte; pH 5.5: 154 ± 11 
pmol/h/oocyte, pH 6.5: 178 ± 11 pmol/h/oocyte and pH 8.0 253 ± 15 pmol/h/oocyte; n=26-33 per 
experimental group), creatine uptake was slightly reduced under more acidic conditions and 
significantly higher under more basic conditions (P <0.0001, ANOVA, pH 8 vs pH 7.4 P <0.05; 
pH 8 vs. pH 6.5 P < 0.001 and pH 8 vs. pH 5.5 P < 0.001, Tukey’s test)(Figure 3C). We further 
tested whether creatine precursors (arginine, glycine and ornithine), creatine breakdown product 
creatinine and the phosphorylated form of creatine interfere with creatine transport by MCT12. 
None of the tested compounds appeared to influence creatine uptake significantly (P<0.5358, 
ANOVA) (experiment 1: creatine only: 225 ± 25 pmol/h/oocyte, arginine: 165 ± 28 
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pmol/h/oocyte, glycine: 168 ± 27 pmol/h/oocyte, ornithine: 164 ± 34 pmol/h/oocyte and 
phosphocreatine: 169 ± 35pmol/h/oocyte; (n=5-7); experiment 2: creatine only: 89 ± 9 
pmol/h/oocyte), creatinine 95 ± 10 pmol/h/oocyte). To allow comparison of all compounds, 
results are displayed as percentage in Figure 3D.  . 
 
SLC16A12 mutation alters transport properties 
In an SLC16A12 mutation screen of patients with age-related cataracts (ARC) we identified a 
novel heterozygous DNA sequence alteration (Figure 4A) that maps to position c.1219G>A; 
p.G407S, affecting an evolutionary highly conserved amino acid that localizes to the last 
extracellular loop. This alteration was not found in 400 alleles from individuals representing the 
general population. Potential development of age-related cataract in this group is unlikely due to 
this sequence alteration. The patient with the c.1219G>A alteration was diagnosed with bilateral 
nuclear cataract with radial cortical opacities in the left eye at the age of 69. To test whether this 
mutation interferes with creatine transport, we generated a construct of SLC16A12 that carries 
this mutation and performed creatine uptake experiments as described above. Injection of 
mutated cRNA into Xenopus laevis oocytes lead to localization of MCT12 at the membrane 
(Figure 1). Noticeably, the uptake of creatine was significantly lowered by 43% (reference 
MCT12: 146 ± 11pmol/h/oocyte and mutant MCT12 p.G407S: 84 ± 9pmol/h/oocyte, P = 0.0004, 
unpaired t-test) (Figure 4B). The mechanism based on which the mutation alters creatine 
transport is not yet known. 
In rats, Slc16a12 knockout animals did neither phenocopy the cataract nor the glucosuria 
phenotype (21) but creatine levels in the urine were significantly elevated (Figure 4C). Knockout 
males accumulated 5.85 mM creatine compaired to 1.76mM in age-matched heterozygous 
knockout males, which corresponds to an approximately 3-fold difference. Likewise, an 
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approximately 2-fold difference was measured in females with 2.12 mM creatine in knockout 
animals versus 1.01mM in age-matched wild type siblings.These results suggest that loss of 
Slc16a12 results in retention of creatine in the urine and a single copy of the gene is suffient for 
creatine transport.  Patients were not available for urine analysis. 
  
Relative expression of SLC16A12 and SLC6A8 displayed tissue-specificity  
Expression of the two genes, SLC16A12 and SLC6A8, encoding the creatine transporters, was 
investigated in various human tissues (Figure 4D). Experimental conditions were chosen to allow 
assessment of the relative expression of the two transcripts within a given tissue, not necessarily 
between all tissues. In the lens, no striking difference was seen in the relative expression of both 
transporters. However, in the kidney and retina, higher relative levels of SLC16A12 were found. 
In brain, heart and muscle tissue, SLC6A8 was more abundant. We concluded, that tissue-specific 
differences in gene expression exist, which are likely to reflect the respective physiological 
functions.      
 
DISCUSSION 
Use of a metabolomics approach in combination with the heterologous Xenopuslaevis oocyte 
expression system resulted in the identification of creatine as the substrate for the solute carrier 
MCT12. This novel combination of technologies is a powerful tool and our results open 
opportunities for substrate identification of many of the remaining orphan transporters. 
Furthermore, application of creatine may provide potential means of prevention of age-related 
cataracts. 
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Characteristics of the transporters 
Until now, the only creatine transporter characterized is CRT1. Here, we present the findings of a 
second creatine transporter CRT2, known as MCT12. While the structural similarities of both 
transporters include the presence of twelve transmembrane domains (25, 27), their activity profile 
is quite distinct. In contrast to MCT12, which performs facilitated transport of creatine, likely 
along a concentration gradient, CRT1 requires sodium and chloride ions and works against the 
creatine concentration gradient (4, 5, 10).  CRT1 is encoded by SLC6A8 on the X chromosome 
(4, 10) and mutations in SLC6A8 lead to mental retardation often combined with speech delay 
and epileptic conditions, but also with muscular dystrophy (10-12).  The expression patterns of 
the two creatine transporters are also distinct: the predominant expression of CRT1 transcripts in 
the brain may correlate well with the observed clinical symptoms of severe developmental delays 
in patients with deficiencies in SLC6A8 (28, 29). Among the various deficiencies in patients with 
SLC6A8 mutations, cataracts, microcornea or glucosuria were not reported. These latter 
symptoms are seen in patients with mutations in SLC16A12 (25) but in turn, these patients did not 
show obvious signs of developmental delay or other neurological disorders. Possibly, 
predominant expression of SLC16A12 compared to SLC6A8 in kidney may help to explain this 
observation. Initial data on membrane localization of the two creatine transporters indicate that 
they occupy opposing sides of epithelial cells; MCT12 seems predominantly at the basolateral 
membrane in lens (21) while CRT1 was found at the apical membrane in proximal tubule cell 
lines and the proximal tubule in rats (8). A possible explanation for transepithelial transport of 
creatine could be invisioned in analogy to the paired transport system described for broad 
specificity, Na+-independent neutral and cation ionic amino acid transporter (30). The absence of 
MCT12 but presence of CRT1 in the proximal convoluted tubule of the kidney of the Slc16a12 
knockout rat would help explain the observed increase spillage of creatine into the urine. It is not 
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uncommon that mutations in genes that are more generally expressed cause highly specific 
clinical symptoms. Whether differences in function or expression or both are responsible for the 
activity of the two transporters need to await further experiments.. 
Proper maturation and localization of monocarboxylate transporters require chaperones (22-24) 
and in HEK293 cells CD147 assumes this task for MCT12 (21). In Xenopus laevis oocytes the 
endogenous level of the CD147 homologue (22) seems sufficient to properly guide the 
transporter to the membrane. Proton environment is known to affect transport activity and pH 
sensitivity known of other members of the MCT family (31) also applies to MCT12 such that 
creatine transport is significantly increased under basic conditions. As MCT12 localizes to the 
lens cortex (21) these findings correlate well with a pH gradient in the lens of a more acidic core 
and a more basic cortex (32-34).  
Aside from MCT12’s involvement in cataract, microcornea and glucosuria, little is known on its 
function and biology. Recently it was reported as biomarker for prostate, colon and breast cancer 
(35). A role of creatine in cancerous tissues is not surprising given that tumor growth is a high 
energy consuming process.  
Function of the substrate creatine 
Creatine is best known for its capacity as energy buffer via phosphocreatine (PCr) (2). High 
levels of PCr are found in skeletal muscle, brain and retina (3) and its presence in the lens was 
established by NMR studies (36), which implies a possible contribution to the energy demand in 
this avascular structure. As differentiated lens fiber cells mainly use glycolysis as energy source 
and do not have any direct oxygen supply from blood vessels (37), an energy buffer such as 
creatine could be advantageous. In this context, the cataract phenotype in patients with mutations 
in SLC16A12 might be explained via altered properties of creatine transport leading to 
disturbance of energy metabolism and resulting in structural changes and opacities within the 
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lens. The relatively high level of PCr in human lens compared to other mammals (36) may 
indicate species-specific variation in its function, which may have contributed to the lack of 
cataracts in Slc16a12 knockout rats (21).  
Furthermore, creatine was found to have antioxidative function (38), which could be beneficial to 
the aging cell. It could act as a mild antioxidant in the lens, which is exposed to environmental 
and molecular factors of oxidative stress (i.e. glutathione) (39). The fact that age-related 
processes like ARC are affected by MCT12 (40) supports this point. In addition, creatine also 
functions as cytoprotective, anti-apoptotic reagent (41, 42). In the lens, an attenuated apoptotic-
like process leads to loss of organelles as part of the differentiating process (43) and creatine 
might play a role in this attenuated process.   
Within the kidney, the involvement of creatine in glucosuria could be envisioned with focus on 
the action of the Na+-K+-ATPase. It generates a sodium gradient, which is required for glucose 
reabsortion in the kidney proximal tubule performed by secondary activity of the sodium-glucose 
linked transporters SGLT1 and 2 (44). As PCr is able to support maximal pump function of the 
Na+-K+-ATPase in kidney cells (45), a possible hypothesis is that disturbance of creatine 
transport could lead to inefficient glucose reabsorption. Alternatively, at a cellular level, renal 
glucosuria could be a response to ER stress, followed by the unfolded protein response, as this 
pathway was recently suggested to influence central metabolic processes, particularly glucose 
metabolism (46). In support is our previously reported finding that the SLC16A12 premature 
termination mutation in patients with renal glucosuria (25) elicits UPR in cell culture (21).   
Taken together, the here reported findings will further our understanding of creatine homeostasis 
and the role of both transporters during this process. Upon further investigations, creatine may 
become a preventive supplement for the most prevalent age-related vision impairment, cataracts.  
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MATERIALS AND METHODS 
Cloning   
The following constructs were generated for the purpose of expression in the heterologous 
Xenopus laevis oocyte system. All restriction enzymes were purchased from Fermentas (St. 
Leon-Rot, DE), unless otherwise stated. As vector we used the BlueScript derived vector KSM, 
(provided by Leila Virkki). The correct DNA sequence of all cloned inserts was verified by 
Sanger sequencing.  For human reference SLC16A12 (ENST00000341233; protein Q6ZSM3) a 
partial sequence in EST clone IRAKp961C20200Q (imaGenes) was completed using cDNA 
gained from HEK293 cells. Isolated RNA (RNeasy Kit; Qiagen) was treated with DNase and 
reverse transcribed using random hexamers for priming and SuperScript III (Invitrogen).  RT-
PCR with template mixture of clone IRAKp961C20200Q and cDNA, primers 
SLC16A12_CL1_for and CL2.2_rev (Table S1) and Pfu DNA Polymerase (Promega) were 
incubated (95°C 2 min; 94 °C 1 min; 55°C 30s; 72°C 4 min; 40x; 72°C 5 min). Human mutation 
SLC16A12 (c.1219G>A) was generated by site directed mutagenesis with the reference clone as 
template and primers SLC16A12_CL1_for, MCT12_1219A_long_f, MCT12_1219T_long_r and 
SLC16A12_CL2.2_rev, specific for the sequence alteration (Table S1) and cloned into KSM. The 
mouse CD147-pOTB7 cDNA was acquired from IMAGE consortium (3589236) and subcloned 
with SalI/NotI into the pCMV-sport6 expression vector.   
In vitro transcription  
KSM clones were linearized with SacII. CD147-pCMV-sport6 was linearized with NheI. In vitro 
transcription was performed using the respective MEGAscript® Kit (Ambion).  
Xenopus laevis ooctes and injections 
Oocytes were surgically removed from Xenopus laevis and treated as described (20). For 
injection, a Nanoject II microinjector (Drummond) was used. A minimum of five oocytes were 
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injected for each experimental condition. Injection volume was 50nl. The amount of cRNA was 
10 ng for CD147 and 20 ng for the transporter. Oocytes were kept at 18°C in ND96 medium 
supplemented with 5mg/L doxacyclin and gentamycin, each. For efflux, 100mM creatine 
supplemented with 10nCi of 14C radiolabeled creatine (Hartmann Analytic) were injected three 
days after cRNA injection. Oocytes were incubated at 25°C in ND96 (please consult 
Suppementary table 1 for medium compositions). Medium aliquots were removed and 
radioactivity was measured using Emulsifier-Safe™ scintillation cocktail (PerkinElmer) and a 
Tri-Carb 2900TR Liquid Scintillation Analyzer (Packard). Efflux was stopped by washing the 
oocytes with ND96. Oocytes were lysed with SDS and radioactivity was measured. For uptake, 
three days after injection, oocytes were washed with ND96 and incubated at 25°C for two 
minutes. ND96 was replaced with 100 µM uptake solution (concentrations ranging from 1 - 3000 
µM were used for Michaelis-Menten kinetics), supplemented with 0.2 µCi 14C radiolabeled 
creatine. After ten minutes, uptake was stopped by removing the uptake solution followed by 
washing the oocytes with ND96. The oocytes were further processed as described for the efflux 
experiments and radioactivity measured. For competition uptake experiments, in addition to 
creatine, 1 mM of arginine, glycine, ornithine, phosophocreatine and creatinine were added. For 
ion- and pH dependency experiments, modified ND96 media supplemented with creatine were 
used (Table S2). Results from all efflux and uptake experiments were statistically analyzed and 
plotted using Prism software (http://www.graphpad.com/scientific-software/prism/). Unpaired-
tests or Michelis-Menten kinetics were applied. Confidence intervals were calculated and 
included in the graphs.  
Cryosectioning 
Three days after injection of cRNA, oocytes were washed in PBS (Gibco) and fixed for two hours 
in 4% paraformaldehyde (PFA) at 4°C and incubated at 4°C in 30% sucrose overnight. Three to 
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five oocytes were placed in a 10x10x5mm Tissue-Tek® Cryomold® (Sakura Finetek) filled with 
Tissue-Tek® (Sekura Finetek) and 7 µm sections were cut using a CM3050 S cryostat (Leica). 
Sections were placed on SuperFrost® slides and stored over night at -20°C.  
Immunofluorescence 
Cryosections were blocked for one hour (PBS containing 0.05% Tween (PBST) and 1% BSA 
(Sigma)). Antibodies against the C-terminal end of human MCT12 (21) (dilution 1:500) and the 
Bandeiraea simplicifolia isolectin B4 FITC conjugate (IB4-FITC, Sigma) (dilution 1:100) were 
applied and the slides incubated overnight at 4°C. Samples treated with IB4-FITC were mounted 
using Fluoromount (Sigma) and coverslips (44).  Samples treated with the MCT12 antibody were 
incubated with secondary goat anti-rabbit IgG Alexa Fluor® 488 (Invitrogen) (1:200 dilution) 
(60 minutes) and mounted. Samples treated with secondary antibody only were included as 
control. Pictures were recorded on an Axioplan 2 imaging system (Zeiss) with an Axiocam MRm 
camera (Zeiss) and processed with Photoshop CS4 (Adobe).   
Transcript Analysis 
RNA of human tissues was obtained from Takara Bio Europe/Clontech (Saint-Germain-en-Laye, 
France). Reverse transcription was performed using Superscript III (Invitrogen). RT-PCR was 
carried out using an annealing temperature of 60 °C and 32 cycles for SLC6A8 (primer pair 
SLC6A8 hum ex6up and SLC6A8 hum ex5dn amplifying a fragment of 150 bp) and SLC16A12 
(primer pair SLC16A12 RNA 4/5f and SLC16A8 RNA 6r). Lens RNA from a donor eye was 3 
fold concentrated using the concentrator 5301 from Eppendorf prior to reverse transcription 
treatment. Resulting cDNA required 41 cycles in RT-PCR (25). 
Creatine assay 
Urine was collected from wildtype (3 female), Slc16a12+/- (3 male) and Slc16a12-/-  (3 female 
and 3 male) rats, then centrifuged at 3'000g for 10 minutes to remove any particulate matter. 
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Supernatants were taken and stored at -80o C. The levels of creatine in the urine of wild type, 
heterozygous and homozygous Slc16a12 male and female rats were measured using the creatine 
assay kit from BioVision. 
Metabolomics 
Sample preparation and handling  
Oocytes were coinjected with SLC16A12 plus CD147 or with CD147 alone and incubated for 
two days. At this point, 20 oocytes per condition were incubated for additional two days in either 
ND96 or rich medium (Table S3), which was supplemented with metabolites mimicking human 
plasma (47, 48) and Kao and Michayluk vitamin mix (Sigma) (49). Oocytes were lysed in ND96 
supplemented with protease inhibitors (Sigma). Samples were centrifuged (4 °C; 25’000 rcf; 5 
minutes). The supernatant was subjected to repeated (2X) centrifugation and concentrated to a 
final volume of 100 µl. For liquid chromatography and mass spectrometry (LC-MS) analysis, 3 
aliquots of 20μL of the oocyte lysates were diluted (1:5) with 50mM ammonium acetate in 
acetonitrile/methanol/water/saturated aqueous ammonium hydroxide (900:90:9:1,v/v, pH 9). All 
reagents, reference compounds and internal standards were purchased from Sigma-Aldrich Fluka 
(Buchs, Switzerland). LiChrosolv grade organic solvents for LC and sample dilution were 
obtained from Merck (Darmstadt, Germany) and HPLC grade water was from Sigma-Aldrich 
(Steinheim, Germany). Hydrophilic interaction chromatography (HILIC) was performed on a 
nano-UPLC system (Waters Inc. Milford, USA). Mobile phase A was 0.5mM ammonium acetate 
in water/saturated aqueous ammonium hydroxide (998:2,v/v, pH 9) and mobile phase B was 
0.5mM ammonium acetate in acetonitrile/water/saturated aqueous ammonium hydroxide 
(950:48:2,v/v, pH 9). A solvent gradient starting from 10%A at initial run time to 50%A at 10min 
run time was applied. The initial flow rate of 6 μl/min was lowered to 4 μL/min at 10min run 
time. The run was completed by a washing phase of 4 minutes at 10%A. Selfmade spray tip 
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columns of 150mm x 0.2mm, packed with Waters BEH Amide type solid phase (1.7µm average 
particle size), were used. 
The UPLC system was coupled by a nano-ESI source to a Synapt G2 HDMS (Waters, 
Manchester, UK). Negative mode MSE data over a mass range of 50-1200m/z were acquired with 
a rate of 3 spectra/sec for the entire UPLC run. Leucine enkephalin (2ng/ μL in acetonitrile/water 
50:50 v/v with 0.1% formic acid v/v) was used as internal lock mass. 
Data Processing and Data Analysis  
Centroided MS data (function 1 of the acquired MSE data) was processed by MarkerLynx XS 4.1 
(Waters, Manchester, UK) to obtain a primary list of [M-H]- ions detected in any of the samples, 
together with its intensity in all samples. This primary list was searched in a data base with a 
mass tolerance of 50mDa and with the assumption that all metabolites only form [M-H]- ions. A 
custom MarkerLynx database containing 3166 exact mass values, metabolite IDs, molecular 
formulas and pathway information of all KEGG listed metabolites (http://www.genome.jp/kegg/) 
was queried. The resulting annotated spectral intensity data matrix of the form n detected masses 
x p samples was imported in an R workspace (www.r-project.org) to perform descriptive 
statistics, univariate and multivariate data analysis. Between Group Analysis (BGA) based on 
correspondence analysis (CoA) was used to detect and visualize metabolites affected by the 
experimental conditions, i.e. potentially transported across the oocyte membrane (R library 
made4, (50)). The intensity data for the top candidates detected by BGA were additionally 
analyzed by 1-way as well as 2-way ANOVA (as appropriate) and visualized by boxplots. 
 
SLC16A12 mutation screen 
Patients with ARC were seen by ophthalmologist (FM) and they gave informed consent. The 
study conformed to the standards set by the Declaration of Helsinki, Conditions for the DNA 
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mutation screen has been described (40). Control individuals represent the general population; 
they were not age-matched and may develop age-related cataract.  
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FIGURE LEGENDS 
Figure 1: Immunofluorescence images.  Membrane localization of hMCT12 in Xenopus laevis 
oocytes injected with SLC16A12 cRNA. Noninjected oocytes and those injected with the 
chaperoneCD147alone served as controls (top row). Membrane localized signals (arrow) were 
detected only in oocytes injected with MCT12, irrespective of the presence of chaperone CD147. 
Figure 2: Creatine is transported by MCT12. A) Significantly lower creatine levels (6.3-fold) 
were detected in oocytes coinjected with SLC16A12 and its chaperone CD147 compared to 
oocytes injected only with CD147. B) Creatine efflux in noninjected oocytes (NI), and oocytes 
expressing CD147 or CD147 + hMCT12. Content of 14C creatine in the medium was recorded as 
percentage of total injected radioactivity at different time points (0, 15 and 60 minutes). C) 
Creatine uptake. Measurements were taken 10 minutes after addition of 14C-creatine to the 
medium of oocytes (NI/CD147/CD147 + hMCT12). Uptake is shown as pmol/hour/oocyte. Bars 
indicate SEM. 
Figure 3: Characterization of creatine uptake. A) Michaelis-Menten kinetics of creatine 
uptake. Vmax =838.8pmol/h/oocyte and Km=567.4 µM. B) Ion dependency of creatine uptake. 
Experiments were performed either in the presence of both sodium and chloride (NaCl) or in 
sodium (Na+) or chloride (Cl-) free medium. C) pH dependency of creatine uptake. pH of 5.5, 6.5, 
7.4 and 8.0 was tested. D) Effect of potential competitors on creatine uptake. Creatine uptake 
alone (creatine) is shown as 100%. Bars indicate SEM.  
Figure 4: Effect of mutations on creatine transport and expression studies.  A) SLC16A12 
mutation screen. Electropherograms of an unaffected individual and of a patient with age-related 
cataract (ARC) showing the heterozygous mutation (arrow) SLC16A12 c.1219G>A, p.G407S   
B) 14C creatine uptake of oocytes expressing the mutant hMCT12p.G407S compared to the 
reference hMCT12. The mutation causes a significant reduction in creatine uptake by 43% (P = 
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0.0004). Uptake was recorded as pmol/hour/oocyte. Bars indicate SEM. C) Creatine levels in 
urine of rats.  Male Slc16a12 knockout (KO) or heterozygous (Het) rats and female KO and 
wildtype (WT). Displayed are the percentages relative to the unaffected males and females at 
100%. Bars indicate SEM. D) Expression of creatine transporter transcripts in human tissues. RT-
PCR using primers specific for SLC16A12 (a) and SLC6A8 (b). Amplicon sizes are given in base 
pairs. Non-template control is water. 
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TABLES 
 
Table 1:  List of substrate candidates for MCT12 obtained from the metabolomics analysis. 
 
Metabolite 
P Value 2 way ANOVA 
with factors injection 
type and medium 
Log2 ratio SLC16A12 
injection over control 
(CD147) 
ADP-ribose 0.1240 3.8570 
L-Glutamine 0.0002 0.9945 
O-Acetyl-L-homoserine 0.0441 0.8344 
7-Methyluric acid 0.0239 0.7736 
Dihydromacarpine 0.3990 0.7188 
3-Amino-2-oxopropyl phosphate 0.415 0.7082 
N-((R)-Pantothenoyl)-L-cysteine 0.0424 0.7034 
L-2,3-Dihydrodipicolinate 0.0100 0.6902 
Cobalt-precorrin 7 0.0900 0.6101 
CDP-choline 0.1982 0.5996 
(-Dihydroorotate 0.0990 -0.5854 
1,4-Naphthoquinone 0.0990 -0.5854 
CDP 0.0967 -0.6050 
UDP-glucuronate 0.3318 -0.6058 
Salicin 0.0054 -0.6659 
Benzo[a]pyrene-7,8-diol 0.0054 -0.6659 
Cellopentaose 0.2726 -0.7048 
5,6-Indolequinone-2-carboxylic acid 0.0002 -0.8816 
3-Hydroxyanthranilate 8.93E-05 -0.9004 
Creatine 3.11E-07 -2.6485 
Statistical significance (2-way ANOVA) and fold change based on observed intensity (log2 
ratio).  
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